In vivo antitumour effect of combretastatin A-4 phosphate added to fractionated irradiation

Anticancer Research

Volumn 26, Issue 1 A, 2006, Pages 307-310

  Ahmed, B ^a   Landuyt, W ^a   Griffioen, A W ^b   Van Oosterom, A ^a   Van Den Bogaert, W ^a   Lambin, P ^a,c  

^a UNIVERSITY OF LEUVEN   (Belgium)

^b MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

^c MAASTRICHT UNIVERSITY   (Netherlands)

Author keywords

Fractionated ionizing radiation; Tumour size effect; Vascular targeting

Indexed keywords

COMBRETASTATIN A4 PHOSPHATE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER INHIBITION; CANCER RADIOTHERAPY; CONTROLLED STUDY; IONIZING RADIATION; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; RHABDOMYOSARCOMA;

ANIMALS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; COMBINED MODALITY THERAPY; DOSE FRACTIONATION; MALE; RATS; RHABDOMYOSARCOMA; STILBENES;

EID: 32144452792     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (21)

1. Denekamp J: Review article: angiogenesis, neovascular proliferation and vascular pathophysiology as targets for cancer therapy. Br J Radiol 66: 181-196, 1993.
2. Folkman J: Tumor angiogenesis. Adv Cancer Res 43: 175-203, 1985.
3. Chaplin DJ, Pettit GR, Parkins CS and Hill SA: Antivascular approaches to solid tumour therapy: evaluation of tubulin binding agents. Br J Cancer 27: S86-88, 1996.
4. Grosios K, Holwell SE, McGown AT, Pettit GR and Bibby MC: In vivo and in vitro evaluation of combretastatin A-4 and its sodium phosphate prodrug. Br J Cancer 81: 1318-1327, 1999.
5. Thorpe PE: Vascular targeting agents as cancer therapeutics. Clin Cancer Res 15;10: 415-427, 2004.
6. Dowlati A, Robertson K, Cooney M, Petros WP, Stratford M, Jesberger J, Rafie N, Overmoyer B, Makkar V, Stambler B, Taylor A, Waas J, Lewin JS, McCrae KR and Remick SC: A phase I pharmacokinetic and translational study of the novel vascular targeting agent combretastatin a-4 phosphate on a single-dose intravenous schedule in patients with advanced cancer. Cancer Res 62: 3408-3416, 2002.
7. Stevenson JP, Rosen M, Sun W, Gallagher M, Haller DG, Vaughn D, Giantonio B, Zimmer R, Petros WP, Stratford M, Chaplin D, Young SL, Schnall M and O'Dwyer PJ: Phase I trial of the antivascular agent combretastatin A4 phosphate on a 5-day schedule to patients with cancer: magnetic resonance imaging evidence for altered tumor blood flow. J Clin Oncol 21: 4428-4438, 2003.
8. Tozer GM, Kanthou C, Parkins CS and Hill SA: The biology of the combretastatins as tumour vascular targeting agents. Int J Exp Pathol 83: 21-38, 2002.
9. Chaplin DJ and Hill SA: The development of combretastatin A4 phosphate as a vascular targeting agent. Int J Radiat Oncol Biol Phys 54: 1491-1496, 2002.
10. Chaplin DJ, Pettit GR and Hill SA: Anti-vascular approaches to solid tumour therapy: evaluation of combretastatin A4 phosphate. Anticancer Res 19: 189-195, 1999.
11. Landuyt W, Verdoes O, Darius DO, Drijkoningen M, Nuyts S, Theys J, Stockx L, Wynendaele W, Fowler JF, Maleux G, Van den Bogaert W, Anne J, van Oosterom A and Lambin P: Vascular targeting of solid tumours: a major 'inverse' volume-response relationship following combretastatin A-4 phosphate treatment of rat rhabdomyosarcomas. Eur J Cancer 36: 1833-1843, 2000.
12. Horsman MR and Murata R: Combination of vascular targeting agents with thermal or radiation therapy. Int J Radiat Oncol Biol Phys 54: 1518-1523, 2002.
13. Siemann DW, Mercer E, Lepler S and Rojiani AM: Vascular targeting agents enhance chemotherapeutic agent activities in solid tumor therapy. Int J Cancer 99: 1-6, 2002.
14. Wildiers H, Ahmed B, Guetens G, De Boeck G, de Bruijn EA, Landuyt W and van Oosterom AT: Combretastatin A-4 phosphate enhances CPT-11 activity independently of the administration sequence. Eur J Cancer 40: 284-290, 2004.
15. Landuyt W, Ahmed B, Nuyts S, Theys J, Op de Beeck M, Rijnders A, Anne J, van Oosterom A, van den Bogaert W and Lambin P: In vivo antitumor effect of vascular targeting combined with either ionizing radiation or anti-angiogenesis treatment. Int J Radiat Oncol Biol Phys 49: 443-450, 2001.
16. Murata R, Siemann DW, Overgaard J and Horsman MR: Interaction between combretastatin A-4 disodium phosphate and radiation in murine tumors. Radiother Oncol 60: 155-161, 2001.
17. Siemann DW, Chaplin DJ and Horsman MR: Vascular-targeting therapies for treatment of malignant disease. Cancer 100: 2491-2499, 2004.
18. Murata R, Overgaard J and Horsman MR: Combretastatin A-4 disodium phosphate: a vascular targeting agent that improves that improves the anti-tumor effects of hyperthermia, radiation, and mild thermoradiotherapy. Int J Radiat Oncol Biol Phys 51: 1018-1124, 2001.
19. Murata R, Siemann DW, Overgaard J and Horsman MR: Improved tumor response by combining radiation and the vascular-damaging drug 5,6-dimethylxanthenone-4- acetic acid. Radiat Res 156: 503-509, 2001.
20. Siemann DW and Rojiani AM: Antitumor efficacy of conventional anticancer drugs is enhanced by the vascular targeting agent ZD6126. Int J Radiat Oncol Biol Phys 53: 164-171, 2002.
21. Garcia-Barros M, Paris F, Cordon-Cardo C, Lyden D, Rafii S, Haimovitz-Friedman A, Fuks Z and Kolesnick R: Tumor response to radiotherapy regulated by endothelial cell apoptosis. Science 300: 1155-1159, 2003.